A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Launched by HK INNO.N CORPORATION · Jan 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Tegoprazan to see how well it works in reducing nighttime heartburn for people with gastroesophageal reflux disease (GERD). Researchers want to compare the effects of Tegoprazan (50mg) to another medication, Esomeprazole (either 40mg or 20mg), to find out which one helps more with nighttime symptoms. The trial is currently looking for participants between the ages of 19 and 75 who have either erosive reflux disease, where the esophagus is damaged, or non-erosive reflux disease, where it is not.

If you decide to join the study, you will undergo some tests, including an upper gastrointestinal (GI) endoscopy, which allows doctors to look at the inside of your esophagus and stomach. However, you cannot participate if you have certain esophageal movement disorders or if you've had surgery that affects how your stomach produces acid. Overall, this trial aims to help improve treatment options for nighttime heartburn in GERD patients, and your participation could contribute to important medical knowledge.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects aged between 19 and 75 years
• • 2. Subjects who have erosive reflux disease or non-erosive reflux disease
• Exclusion Criteria:
• • 1. Unable to undergo upper GI endoscopy
• • 2. Symptoms of primary or secondary esophageal movement disorders
• • 3. Subjects who have undergone or are scheduled to undergo surgery that can affect gastric acid secretion(e.g. upper gastrectomy, vagotomy, etc)